SciSparc (SPRC) Competitors

SciSparc (NASDAQ:SPRC) and OncoCyte (NASDAQ:OCX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, community ranking, media sentiment, earnings and analyst recommendations.

Does the media refer more to SPRC or OCX?

In the previous week, SciSparc had 1 more articles in the media than OncoCyte. MarketBeat recorded 3 mentions for SciSparc and 2 mentions for OncoCyte. OncoCyte's average media sentiment score of 1.46 beat SciSparc's score of 0.61 indicating that OncoCyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SciSparc	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OncoCyte	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is SPRC or OCX more profitable?

SciSparc has a net margin of 0.00% compared to OncoCyte's net margin of -6,122.29%. SciSparc's return on equity of 0.00% beat OncoCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SciSparc	N/A	N/A	N/A
OncoCyte	-6,122.29%	-269.32%	-59.71%

Does the MarketBeat Community favor SPRC or OCX?

OncoCyte received 7 more outperform votes than SciSparc when rated by MarketBeat users. However, 66.67% of users gave SciSparc an outperform vote while only 8.33% of users gave OncoCyte an outperform vote.

Company	Underperform	Outperform
SciSparc	Outperform Votes 2 66.67%	Underperform Votes 1 33.33%
OncoCyte	Outperform Votes 9 8.33%	Underperform Votes 99 91.67%

Which has higher earnings and valuation, SPRC or OCX?

SciSparc has higher revenue and earnings than OncoCyte.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SciSparc	$2.88M	2.15	-$5.12M	N/A	N/A
OncoCyte	$1.50M	23.34	-$27.78M	N/A	N/A

Do analysts rate SPRC or OCX?

OncoCyte has a consensus price target of $4.42, indicating a potential upside of 112.34%. Given OncoCyte's stronger consensus rating and higher probable upside, analysts clearly believe OncoCyte is more favorable than SciSparc.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SciSparc	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
OncoCyte	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Do insiders & institutionals believe in SPRC or OCX?

25.1% of SciSparc shares are owned by institutional investors. Comparatively, 55.4% of OncoCyte shares are owned by institutional investors. 1.5% of SciSparc shares are owned by insiders. Comparatively, 1.6% of OncoCyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Which has more volatility and risk, SPRC or OCX?

SciSparc has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500. Comparatively, OncoCyte has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.

Summary

OncoCyte beats SciSparc on 9 of the 16 factors compared between the two stocks.